{
    "eid": "2-s2.0-85144581202",
    "title": "Target Identification of 22-(4-Pyridinecarbonyl) Jorunnamycin A, a Tetrahydroisoquinoline Derivative from the Sponge Xestospongia sp., in Mediating Non-Small-Cell Lung Cancer Cell Apoptosis",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Analytical Chemistry",
            "@code": "1602",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Chemistry (miscellaneous)",
            "@code": "1601",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmaceutical Science",
            "@code": "3003",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Physical and Theoretical Chemistry",
            "@code": "1606",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Organic Chemistry",
            "@code": "1605",
            "@abbrev": "CHEM"
        }
    ],
    "keywords": [
        "22-(4-pyridinecarbonyl) jorunnamycin A",
        "apoptosis",
        "mitogen-activated protein kinase",
        "network pharmacology",
        "non-small cell lung cancer"
    ],
    "authors": [
        "Iksen Iksen",
        "Suwimon Sinsook",
        "Onsurang Wattanathamsan",
        "Koonchira Buaban",
        "Supakarn Chamni",
        "Varisa Pongrakhananon"
    ],
    "citedby-count": 2,
    "ref-count": 55,
    "ref-list": [
        "Epidemiology of lung cancer",
        "Lung cancer: A review",
        "Lung cancer",
        "Chemotherapy resistance in lung cancer",
        "Non-small-cell lung cancer: Treatment of late stage disease: Chemotherapeutics and new frontiers",
        "Marine natural products: A source of novel anticancer drugs",
        "Therapeutic application of diverse marine-derived natural products in cancer therapy",
        "5-O-(N-Boc-l-Alanine)-Renieramycin T induces cancer stem cell apoptosis via targeting Akt signaling",
        "Chemical research on antitumor isoquinoline marine natural products and related compounds",
        "Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification",
        "Hydroquinone 5-O-Cinnamoyl ester of renieramycin M suppresses lung cancer stem cells by targeting Akt and destabilizes c-Myc",
        "Trabectedin for soft tissue sarcoma: Current status and future perspectives",
        "FDA approval summary: Trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen",
        "Trabectedin, a drug acting on both cancer cells and the tumour microenvironment",
        "Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial",
        "Chemistry of DNA minor groove binding agents",
        "Anticancer and antimetastatic activities of renieramycin M, a marine tetrahydroisoquinoline alkaloid, in human non-small cell lung cancer cells",
        "Renieramycin M sensitizes anoikis resistant H460 lung cancer cells to anoikis",
        "Renieramycin M attenuates cancer stem cell-like phenotypes in H460 lung cancer cells",
        "Jorunnamycin A from Xestospongia Sp. suppresses epithelial to mesenchymal transition and sensitizes anoikis in human lung cancer cells",
        "Jorunnamycin A suppresses stem-like phenotypes and sensitizes cisplatin-induced apoptosis in cancer stem-like cell enriched spheroids of human lung cancer cells",
        "Chemistry of renieramycins. Part 8: Synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues. Bioorg",
        "Chemistry of renieramycins. 15. Synthesis of 22- O -ester derivatives of jorunnamycin A and their cytotoxicity against non-small cell lung cancer cells",
        "Targeting apoptosis in cancer therapy",
        "Epidermal growth factor receptor cell proliferation signaling pathways",
        "Paclitaxel",
        "An in vitro high-throughput assay for screening reproductive and toxic effects of anticancer compounds",
        "Protein-protein interactions and selection: Array-based techniques for screening disease-associated biomarkers in predictive/early diagnosis",
        "Integrative approach in the era of failing drug discovery and development",
        "Network pharmacology: The next paradigm in drug discovery",
        "Network pharmacology",
        "Network pharmacology: A new approach for chinese herbal medicine research. Evid. Based. Complement",
        "B-nor-methylene colchicinoid PT-100 selectively induces apoptosis in multidrug-resistant human cancer cells via an intrinsic pathway in a caspase-independent manner",
        "ERK/MAPK signalling pathway and tumorigenesis",
        "The crosstalk between sTAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT mediated regulation of EMT and autophagy",
        "Lipocalin-2 inhibits osteosarcoma cell metastasis by suppressing MET expression via the MEK-ERK pathway",
        "Lupalbigenin from Derris scandens sensitizes detachment-induced cell death in human lung cancer cells",
        "Colicin N mediates apoptosis and suppresses integrin-modulated survival in human lung cancer cells",
        "Correction: Erianthridin induces non-small cell lung cancer cell apoptosis through the suppression of extracellular signal-regulated kinase activity",
        "MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer",
        "Anti-tumor and Anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer",
        "Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway",
        "In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics",
        "GeneCards version 3: The human gene integrator",
        "Therapeutic target database update 2022: Facilitating drug discovery with enriched comparative data of targeted agents",
        "OMIM.Org: Leveraging knowledge across phenotype-gene relationships",
        "DisGeNET-RDF: Harnessing the innovative power of the semantic web to explore the genetic basis of diseases",
        "SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules",
        "Cytoscape: A software environment for integrated models of biomolecular interaction networks",
        "STRING V11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets",
        "CytoHubba: Identifying hub objects and sub-networks from complex interactome",
        "KEGG: Kyoto encyclopedia of genes and genomes",
        "Loss of CAMSAP3 promotes EMT via the modification of microtubule-Akt machinery"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Second Century Fund",
        "Thailand Science Research and Innovation Fund Chulalongkorn University",
        "National Research Council of Thailand"
    ]
}